acalabrutinib + venetoclax

**Acalabrutinib + venetoclax** is a combination of two targeted small-molecule drugs under investigation for the treatment of B-cell malignancies, especially **chronic lymphocytic leukemia (CLL)** and **small lymphocytic lymphoma (SLL)**. Acalabrutinib is a selective inhibitor of Bruton's tyrosine kinase (BTK), a key enzyme in B-cell receptor signaling that promotes malignant B-cell survival and proliferation. Venetoclax is a selective inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein overexpressed in many B-cell malignancies that prevents programmed cell death of malignant cells. The rational for this combination is their **complementary mechanisms of action**, resulting in more effective eradication of malignant cells and improved outcomes compared to monotherapies. This combination is currently the subject of phase II and phase III clinical trials and under regulatory review for frontline CLL/SLL therapy[1][7][5]. It is not approved as a fixed-duration combination, though each component is individually approved for CLL/SLL.

Other names

AVacalabrutinib-venetoclax